Supernus (SUPN) Pharmaceuticals has completed its previously announced acquisition of Sage Therapeutics (SAGE). “Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Cantor upgrades Supernus on outlook for ADHD treatment
- Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald
- Supernus announces expiration of HSR waiting period for Sage Therapeutics
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Supernus Pharmaceuticals Holds Annual Stockholders Meeting